

**Larkana Institute of Nuclear Medicine and Radiotherapy
(LINAR)**

P.O. Box No. 05
(Ph. No. 074-9410322 – Fax No. 074-9410729)
Email: linarlarkana@paec.gov.pk




**TERMS & CONDITIONS FOR THE PURCHASE OF ANTI CANCER MEDICINES / DRUGS
OUT OF PAKISTAN BAIT-UL-MAL FUNDS FOR 02 YEARS (2026-27 & 2027-28)**


1. The Validity of tender should be for a period of 02 years i.e. Financial Year 2026-27 & 2027-28.
2. The supply will be made at LINAR, Larkana within seven (07) days of the receipt of supply order.
3. Tender will be based on **Single Stage 02 Envelop** process i.e. **Technical and Financial** weightage will be 70% + 30% respectively.
4. Quotation/Bid must be accompanied with 1% Security Deposit / Earnest Money of the total estimated value in favor of Head LAO, LINAR. Quotation / Bid received without Earnest Money will not be considered for competition.
5. The medicines will be purchased from supplier through LCPWS Pharmacy. LCPWS Pharmacy will raise supply order and arrange stocking and issuance of the medicines to the patients. Payment will also be made through LCPWS Pharmacy to the supplier.
6. The amount of Security Deposit / Earnest Money will be returned to the un-successful bidders after finalization of the case.
7. The amount of call deposit will be forfeited in case the Firm/Supplier fails to supply the medicines as per our specification.
8. The Supplier/Firm having bad reputation/Blacklisted with any Government Organization etc. may not apply at all.
9. The firms who fail to supply the store up to the requisite quantity, quality and specification within the delivery date/specified time, the purchaser will have the right to confiscate the earnest Money/Security sent along-with the quotation/tender and cancel the order/contract and purchase the store elsewhere at risk and cost of the firm which fails to supply for which no notice shall be issued and the purchaser will not be responsible for any loss that firm may suffer due to the cancellation of the order/contract, or in such a case the purchaser may either impose a penalty on firm to be paid by the firm by the way of liquidated damages at the rate of 2% of the value of un-supplied store per day for the number of days by which the delivery is delayed and beyond the said date/specified time up to a maximum of 10% of the total contract value.
10. Lists of the medicines are attached with dosage form.
11. Income Tax as per rules of Govt. shall be deducted on all supply.


Contd...P/2


12. The supplier will have to submit authorized distributorship certificate from the concerned -pharmaceutical companies at the time of tender.
13. The final selection will be made on the total final marks Technical +Financial base.
14. Initially Technical bids will be opened. Evaluation of the Technical bids will be done as per standard criteria, given along with this document. Financial bids will be opened after evaluation of technical bids.
15. All articles supplied shall be in accordance with the specification contained in the supply order.
16. All medicines supplied shall be subject to the inspection by the Inspection Officer (Store)/Inspection Board of this Institute.
17. While supplying the medicines, only those medicines will be supplied which have the maximum expiry date available in the market not less than 70% of it shelf life. In this regard, supplier shall submit an undertaking on a Non-Judicial Stamp Paper i.e. (valuing to Rs.100/-for replacement of all near expiry medicines with fresh stock. LINAR reserves the right to reject any or all the medicines which are not in accordance with our specification /requirement, standard, quality, quantity or size contained in the supply order.
18. Supplier shall produce necessary Cheque acknowledgement receipt of payment made to them through crossed Cheque.
19. The rates submitted must be in terms of smallest unit price i.e. per Tab, per capsules or per Injection. in format given with this document. Quotation must be submitted strictly in the format & serial number Separate provided in the tender documents. Failing in doing so, may lead to rejection of the bid.
20. Documents in language other than English will not be acceptable.
21. The supplier will be responsible to maintain the cold chain of the medicines if applicable. For any quality compromise due to cold breakage, the supplier will be held responsible.
22. The competent authority reserves the right to accept or reject any quotation/tender or part thereof without assigning any reason in writing.

Note: In case if any firm/party, does not agree with the above cited Terms & Conditions, They need not to participate in the tender.



Abdul Razaque Bhutto
Per. Staff Officer / Member



Zohaib Jamil
Admin Officer/Member



Faheem Imtiaz
Head LAO/Member



Jamil Ahmed
IT Coordinator/Member

Approved


Irshadullah Rashdi
Supervisor
Pharmacy/Member


Dr. Hafeezullah
Soomro
PMO/Convener


Dr. Abdul Samad
Director, LINAR



Larkana Institute of Nuclear Medicine and Radiotherapy
(LINAR)
P.O. Box No. 05
(Ph. No. 074-9410322 – Fax No. 074-9410729)
Email: linarlarkana@paec.gov.pk



Technical Evaluation Criteria

Total Marks: 70

Only those drugs should be quoted which are:

- i) Registered with Ministry of Health/Drug Regulatory Authority of Pakistan (DRAP)
- ii) Register for use in their country of origin.

Sr.#	Parameters	Details	Maximum Marks	Remarks
1	Product Registration	Category A 1) US FDA 2) EMA(Western Europe) 3) MHRA UK 4) TGA Australia 5) PHARMAC, New Zealand 6) PMDA Japan 7) Swiss-Medic Switzerland 8) Health Canada 9) HAS Singapore	30	
		Category B 1) EMA (Central or Eastern Europe) 2) ANVIS Brazil 3) CDSCO India 4) NPCB Malaysia 5) FDA South Korea 6) MOH Egypt 7) MOH Turkey 8) FDA China 9) ANMAT Argentina 10) DRA Pakistan 11) Or any other Authority not mentioned in Category A.	20	
2.	Country of Manufacturing	Category A 1)US 2) Western Europe 3)UK 4)Australia 5) New Zealand 6)Japan 7)Switzerland 8)Canada 9)Singapore	20	
		Category B 1 (Central or eastern Europe) 2) Brazil 3) India 4) Malaysia 5) South Korea 6) Egypt	10	

		7) Turkey 8) China 9) Argentina 10) Pakistan 11) Or any other Authority not mentioned in Category A		
3	Bio-Availability / Bio-Equivalence / Bio-Similar Certificate	Whatever and wherever applicable	4	5 Marks will also be given in case where none is applicable for certain formulations.
4	Cold Chain Certificate	Affidavit to be provided on Rs.100 Stamp Paper.	3	-
5.	Marketing / Export / Registration Proof	At least 5 Other countries	3	Only for Developed or at least Developing Countries.
6	Past Performance	Substantial Quantity Supplied to the following hospitals in last 02 Years namely: 1. Agha Khan University Hospital Karachi 2. Liaqat National Hospital, Karachi 3. Ziauddin Hospital 4. Civil / Dow Hospital, Karachi, 5. KIRAN, Karachi	10	02 marks for supply to each institute with invoice proof clearly showing date and quantity of supply. And also a "Good Performance Certificate" will be needed from the institute to which the supplies are made.


Abdul Razaque Bhutto
Per. Staff Officer / Member


Zohaib Jamil
Admin Officer/Member



Faheem Imtiaz
Head LAO/Member



Jamil Ahmed
IT Coordinator/Member


Irshadullah Rashdi
Supervisor Pharmacy/Member


Dr. Hafeezullah Soomro
PMO/Convener

Approved By


Dr. Abdul Samad
Director, LINAR



Larkana Institute of Nuclear Medicine and Radiotherapy
(LINAR)
P.O. Box No. 05
(Ph. No. 074-9410322 – Fax No. 074-9410729)
Email: linarlarkana@paec.gov.pk



Financial Weightage Formula

Total Marks.30

$$\text{Financial Marks } F = \frac{(A)}{B} \times 30$$

A is the price of lowest quoted drug.

B is the price of product under consideration

Note: Selection will be made on the basis of sum of the Technical and Financial Marks.

The highest Marks Products will be selected.

Abdul Razaque Bhutto
Per. Staff Officer / Member

Zohaib Jamil
Admin Officer/Member

Faheem Imtiaz
Head LAO/Member

Jamil Ahmed
IT Coordinator/Mem

Approved By

Irshadullah Rashdi
Supervisor Pharmacy/Member

Dr. Hafaezullah Soomro
RMO/Convener

Dr. Abdul Samad
Director, LINAR

Larkana Institute of Nuclear Medicine and Radiotherapy (LINAR)

List of Medicines - LINAR, Larkana for the FY - 2026-27 & 2027-28

SR. NO	Dosage/ Form	Generic Name	Potency/ Strength	Brand Name	Bid Cost of Unit (Rs.)
1	Tab.	Abiraterone	250 mg		
2	Tab.	Anestrezole	01 mg		
3	Inj.	Azacitadine	100 mg		
4	Cap.	Aprepitant	125 mg		
5	Cap.	Aprepitant	80 mg		
6	Cap.	Atra	10 mg		
7	Inj.	Ado-transtuzumab	100mg		
8	Inj.	Ado-transtuzumab	160mg		
9	Inj.	Atezolizumab	1200mg		
10	Inj.	Alecitinib	150mg		
11	Tab.	Abemaciclib	150 mg		
12	Tab.	Antaforacinab	50 mg		
13	Tab.	Afatinib	40 mg		
14	Inj.	BCG	40 mg		
15	Tab.	Bicalutamide	50 mg		
16	Inj.	Bleomycin	15 mg		
17	Inj.	Bevacizumab (Avastin)	100 mg		
18	Inj.	Bevacizumab (Avastin)	400 mg		
19	Inj.	Bendamustine	100 mg		
20	Inj.	Bortizomib	2 mg		
21	Inj.	Bortizomib	3.5 mg		
22	Tab.	Busalphan	2 mg		
23	Inj.	Cabazitaxel	60 mg		
24	Cap.	Capcitabine	500 mg		
25	Cap.	CCNU	400 mg		
26	Inj.	Ceutuximab	5 mg		
27	Inj.	Carboplatin	150 mg		
28	Inj.	Carboplatin	450 mg		
29	Inj.	Carfizomib	60 mg		
30	Inj.	Carmustine	100 mg		
31	Inj.	Cisplatin	50 mg		
32	Inj.	Cisplatin	10 mg		
33	Inj.	Cituximab	100 mg		
34	Tab.	Chlorambucil	2 mg		
35	Inj.	Cladribine	10 mg		
36	Inj.	Cyclophosphamide	1000 mg		
37	Inj.	Cyclophosphamide	500 gm		
38	Inj.	Cyterabine	100 mg		
39	Inj.	Cyterabine	1000 gm		
40	Inj.	Cyclosporine	100 mg		
41	Tab.	Cyclophosphamide	50 mg		
42	Tab.	Cyclophosphamide Acetate	50 mg		
43	Cap.	Crizotinib	250 mg		
44	Inj.	Dacarbazine	200 mg		
45	Inj.	Dactinomycine	0.5 mg		
46	Inj.	Daunorubicine	20 mg		
47	Inj.	Decitabine	50 mg		

SR. NO	Dosage/ Form	Generic Name	Potency/ Strength	Brand Name	Bid Cost of Unit (Rs.)
48	Inj.	Denosumab	60 mg		
49	Inj.	Denosumab	120 mg		
50	Inj.	Docetaxel	20 mg		
51	Inj.	Docetaxel	80 mg		
52	Inj.	Docetaxel	120 mg		
53	Inj.	Doxorubicine	10 mg		
54	Inj.	Doxorubicine	50 mg		
55	Inj.	Etoposide	50 mg		
56	Cap.	Etoposide	50 mg		
57	Cap.	Enzalutamide	50 mg		
58	Inj.	Epirubicine	40 mg		
59	Inj.	Epirubicine	10 mg		
60	Tab.	Erlotinib	50 mg		
61	Tab.	Erlotinib	100 mg		
62	Tab.	Everolimus (Afinitor)	150 mg		
63	Tab.	Everolimus (Afinitor)	05 mg		
64	Tab.	Exemastine	10 mg		
65	Tab.	Eltrombopag	25 mg		
66	Tab.	Eltrombopag	25mg		
67	Inj.	Filgstin	50mg		
68	Inj.	Fluorouracil	300 ugm		
69	Inj.	Fluorouracil	250 mg		
70	Tab.	Flutamide	500 mg		
71	Tab.	Folinic Acid	250 mg		
72	Inj.	Folinic Acid	15 mg		
73	Inj.	Folinic Acid	50 mg		
74	Inj.	Fluderabin	100 mg		
75	Inj.	Fulvesturant	50 mg		
76	Inj.	Gazyva (Obinotuzumab)	250 mg		
77	Cap.	Gefitinib	420 mg		
78	Inj.	Gemcitabine	250 mg		
79	Inj.	Gemcitabine	200 mg		
80	Inj.	Goserline	1000 mg		
81	Inj.	Granisetrone	3.06 mg		
82	Tab.	Granisetrone	3 mg		
83	Cap.	Hydroxy Urea	1 mg		
84	Cap.	Ibrutinib	500 mg		
85	Inj.	Ifosfamide	140 mg		
86	Inj.	Ifosfamide	1000 gm		
87	Inj.	Idarubicine	2000 gm		
88	Inj.	Idarubicine	5 mg		
89	Inj.	Idarubicine	10 mg		
89	Tab.	Imatinib	100 mg		
90	Tab.	Imatinib	400 mg		
91	Inj.	Interleukin-II	1.5 mg		
92	Inj.	Interleukin-II	3 mg		
93	Inj.	Irinotecan	40 mg		
94	Inj.	Irinotican	100 mg		
95	Cap.	Ibrutinib	140 mg		
96	Tab.	Lapatinib	250 mg		
97	Inj.	L-Asparaginase	1000 mg		
98	Tab.	Letrozole	3.75 mg		

SR. NO	Dosage/ Form	Generic Name	Potency/ Strength	Brand Name	Bid Cost of Unit (Rs.)
99	Inj.	Leuproline	3.75 mg		
100	Inj.	Leuproline	7.5 mg		
101	Inj.	Leuproline	11.25 mg		
102	Cap.	Lenalidomide	10 mg		
103	Cap.	Lenalidomide	25 mg		
104	Inj.	Liposomal Doxorubicine	20 mg		
105	Tab.	Lenvatinib	4 mg		
106	Tab.	Lenvatinib	10 mg		
107	Inj.	Mechlorethamine	10 mg		
108	Tab.	Medroxy Progesterone	200 mg		
109	Tab.	Medroxy Progesterone	400 mg		
110	Tab.	Megestrol Asetate	160 mg		
111	Tab.	Melfalan	2 mg		
112	Tab.	Methotrexate	2.5 mg		
113	Tab.	Methotrexate	10 mg		
114	Inj.	Mesna	400 mg		
115	Inj.	Methotrexate	10 mg		
116	Inj.	Methotrexate	50 mg		
117	Inj.	Mitomycin	10 mg		
118	Inj.	Mitomycin	20 mg		
119	Tab.	Nilotinib	150 mg		
120	Inj.	Nivolumab	50 mg		
121	Inj.	Nivolumab	100 mg		
122	Tab.	Nilotinib	200 mg		
123	Tab.	Nab-Paclitaxel	100 mg		
124	Inj.	Octreotide LAR	20 mg		
125	Inj.	Octreotide LAR	30 mg		
126	Inj.	Ondansetrone	8 mg		
127	Inj.	Ondansetrone	8 mg		
128	Tab.	Ondansetron	8 mg		
129	Tab.	Osimertinib	80 mg		
130	Inj.	Oxaliplatin	50 mg		
131	Inj.	Oxaliplatin	100 mg		
132	Inj.	Oxaliplatin	150 mg		
133	Tab.	Olaparib	150 mg		
134	Inj.	Paclitaxil	30 mg		
135	Inj.	Paclitaxel	100 mg		
136	Inj.	Paclitaxel	150 mg		
137	Inj.	Paclitaxil	260 mg		
138	Inj.	Paclitaxel	300 mg		
139	Inj.	Pamidronate	30 mg		
140	Tab.	Pazopanib	200 mg		
141	Tab.	Pazopanib	400 mg		
142	Inj.	Pembrolizumab	100 mg		
143	Inj.	Peg Asperginase	3750 IU		
144	Inj.	Peg Filgristime	6 mg		
145	Inj.	Pertuzumab	420 mg		
146	Inj.	Pemetrexate	100 mg		
147	Cap.	Procarbazine	50 mg		
148	Tab.	Ribociclib	200 mg		
149	Inj.	Rituximab	100 mg		

SR. NO	Dosage/ Form	Generic Name	Potency/ Strength	Brand Name	Bid Cost of Unit (Rs.)
150	Inj.	Rituximab	500 mg		
151	Inj.	Rituximab SC	1400mg		
152	Tab.	Ruxolotinib	5 mg		
153	Tab.	Ruxolotinib	15 mg		
154	Tab.	Ruxolotinib	20 mg		
155	Tab.	Sorofinib	200 mg		
156	Tab.	Sunitinib	12.5 mg		
157	Tab.	Sunitinib	25 mg		
158	Tab.	Sunitinib	50 mg		
159	Cap.	Temozalomide	20 mg		
160	Cap.	Temozolamide	100 mg		
161	Cap.	Temozalomide	250 mg		
162	Tab.	Temoxifen	10 mg		
163	Tab.	Temoxifen	20 mg		
164	Cap.	Thalidomide	50 mg		
165	Cap.	Thalidomide	100 mg		
166	-	Thermoplastic Sheet	Head & Neck		
167	-	Thermoplastic Sheet	Breast		
168	-	Thermoplastic Sheet	Pelvis Small		
169	Inj.	Transtzumab	440 mg		
170	Inj.	Transtzumab SC	600 mg		
171	Inj.	Tropositron	05 mg		
172	Cap.	Tropositron	5 mg		
173	Inj.	Topotecane	04 mg		
174	Inj.	Transtzumab	150mg		
175	Inj.	Vinblastine	10 mg		
176	Inj.	Vincristine	01 mg		
177	Inj.	Vincristine	02 mg		
178	Inj.	Vinorelbine	10 mg		
179	Inj.	Vinorelbine	30 mg		
180	Inj.	Vinorelbine	50 mg		
181	Inj.	Zolideronic Acid	4 mg		
182	Inj.	Leuproline	22.5mg		
183	Inj.	Polatuzumab	140mg		
184	Cap.	Palbociclib	100 mg		
185	Cap.	Palbociclib	125 mg		
186	Inj.	Palonosetron	0.25 mg		
187	Tab.	Regorafenib	40 mg		
188	Tab.	Pazopanib	200 mg		
189	Inj.	Pemetrexate	500mg		
190		Other Anti Cancer Medicines			

13

[Handwritten signature]

[Handwritten signature]

Prashant

[Handwritten signature]